Methyl aminolevulinate
- L01XD03 (WHO)
- Methyl 5-amino-4-oxopentanoate
- 33320-16-0
Y
- 157922
- DB00992
Y
- 13180320
Y
- 585NM85KYM
- ChEMBL1096562
N
- DTXSID3048570
- Interactive image
- O=C(CC(N)C(=O)OC)C
- InChI=1S/C6H11NO3/c1-4(8)3-5(7)6(9)10-2/h5H,3,7H2,1-2H3
Y
- Key:FLQHIIVXMKXKFT-UHFFFAOYSA-N
Y
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Methyl aminolevulinate (MAL) is a drug used as a sensitizer in photodynamic therapy. It is a prodrug that is metabolized to protoporphyrin IX. It is marketed as Metvix.
Metvix cream is applied topically and some time later the skin is illuminated with a proprietary red light (630 nm) source (medical lamp 'Aktilite') to activate the photosensitiser.
Metvix is developed by Photocure and Galderma has bought all rights to Metvix.[1]
Approvals and indications
![](http://upload.wikimedia.org/wikipedia/commons/thumb/d/d3/Phototherapy_week.png/220px-Phototherapy_week.png)
Methyl aminolevulinate is approved in New Zealand for treatment of basal cell carcinoma.[2]
It is now approved in many countries and has been used to treat non-melanoma skin cancer (including basal cell carcinoma).[3]
It has some advantages over Levulan.[4]
It has been reported as controversial in some quarters, with severe pain allegedly being experienced by some patients. [5]
References
- ^ "Photocure Divests Metvix to Galderma for EUR 51 Million". Archived from the original on 2011-02-07. Retrieved 2010-09-10.
- ^ Ngan V (2003). "Methyl aminolevulinate photodynamic therapy (MAL PDT)". DermNet NZ.
- ^ "New 5 Year Metvix-PDT Data Demonstrate Long-Term Efficacy & Reliability For NM Skin Cancer Treatment". EurekAlert!. 2006.
- ^ O'Connor AE, Gallagher WM, Byrne AT (2009). "Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy". Photochemistry and Photobiology. 85 (5): 1053–74. doi:10.1111/j.1751-1097.2009.00585.x. PMID 19682322. S2CID 205950773.
- ^ "Concerns raised over ALA skin cancer cream as patients recount 'horrendous' pain". Australian Broadcasting Corporation. 16 November 2013.
- v
- t
- e
(M phase)
Block microtubule assembly | |
---|---|
Block microtubule disassembly |
inhibitor
DNA precursors/ antimetabolites (S phase) |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Topoisomerase inhibitors (S phase) |
| ||||||||
Crosslinking of DNA (CCNS) |
|
- Aminolevulinic acid
- Efaproxiral
- Methyl aminolevulinate
- Padeliporfin
- Porphyrin derivatives (Porfimer sodium
- Talaporfin
- Temoporfin
- Verteporfin)
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III